Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
The present invention provides compositions useful for treating and preventing ryanodine receptor associated disorders comprising a PDE-associated agent and a pharmaceutically acceptable carrier. The present invention also provides methods for treating or preventing ryanodine receptor associated disorders including cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases malignant hyperthermia, diabetes and sudden infant death syndrome. The present invention further provides methods for regulating PKA phosphorylation of a ryanodine receptor as well as methods for regulating Ca+2 release and reuptake in cells. Also provided are kits for use in delivering a PDE-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter.
1 . A composition useful for treating or preventing a ryanodine receptor associated disorder comprising:
(a) a phosphodiesterase (PDE)-associated agent; and optionally
(b) a pharmaceutically acceptable carrier.
2 . The composition of claim 1 , wherein the PDE-associated agent is selected from the group consisting of a PDE protein, a nucleic acid encoding a PDE protein, a member of a PDE signal-transduction pathway, and a modulator of a member of a PDE signal transduction pathway.
3 . The composition of claim 2 , wherein the PDE-associated agent is PDE4D protein or a nucleic acid encoding PDE4D.
4 . The composition of claim 1 , wherein the ryanodine receptor associated disorder is a RyR1 associated disorder.
5 . The composition of claim 1 , wherein the ryanodine receptor associated disorder is a RyR2 associated disorder.
6 . The composition of claim 1 , wherein the ryanodine receptor associated disorder is a RyR3 associated disorder.
7 . A method for treating or preventing a ryanodine receptor associated disorder in a subject comprising augmenting PDE in a ryanodine receptor complex of the subject.
8 . The method of claim 7 , wherein the PDE is augmented in the ryanodine receptor complex by contacting the ryanodine receptor complex with a PDE-associated agent.
9 . The method of claim 8 , wherein the PDE-associated agent is selected from the group consisting of a PDE protein, a nucleic acid encoding a PDE, a member of a PDE signal-transduction pathway, and a modulator of a member of a PDE signal transduction pathway.
10 . The method of claim 7 , wherein the PDE is PDE4D.
11 . The method of claim 7 , wherein the PDE is PDE4D3.
12 . The method of claim 7 , wherein the ryanodine receptor is RyR1.
13 . The method of claim 7 , wherein the ryanodine receptor is RyR2.
14 . The method of claim 7 , wherein the ryanodine receptor is RyR3.
15 . The method of claim 7 , wherein the subject is human.
16 . The method of claim 7 , wherein the ryanodine receptor associated disorder is selected from the group consisting of: cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome.
17 . The method of claim 16 , wherein the cardiac disorder and diseases are selected from the group consisting of irregular heartbeat disorders and diseases; exercise-induced irregular heart beat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure.
18 . The method of claim 17 , wherein the irregular heartbeat disorders and diseases and exercise-induced irregular heartbeat disorders and diseases are selected from the group consisting of atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catechlaminergic polymorphic ventricular tachycardia (CPTV); and exercise-induced variants thereof.
19 . The method of claim 16 , wherein the skeletal muscular disorder and diseases are selected from the group consisting of skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence.
20 . The method of claim 16 , wherein the cognitive disorders and diseases are selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
21 . The method of claim 7 , wherein the agent increases the expression of PDE gene in the subject.
22 . A kit for use in delivering a PDE-associated agent to a ryanodine receptor complex in a subject, comprising: (a) the PDE-associated agent of claim 8; (b) a catheter; and optionally (c) a pharmaceutically acceptable carrier.
23 . A method for regulating PKA phosphorylation of a ryanodine receptor comprising contacting the ryanodine receptor complex with an agent that modulates the level of PDE in the ryanodine receptor complex, wherein contacting the ryanodine receptor complex with an agent that increases the level of PDE in the complex results in a reduction of PKA phosporylation of the ryanodine receptor, and contacting the ryanodine receptor complex with an agent that decreases the level of PDE in the complex results in an increase of PKA phosporylation of the ryanodine receptor.
24 . The method of claim 23 , wherein the agent is selected from the group consisting of a PDE protein, a nucleic acid encoding a PDE, a member of a PDE signal-transduction pathway, and a modulator of a member of a PDE signal transduction pathway.
25 . The method of claim 23 , wherein the PDE is PDE4D.
26 . The method of claim 25 , wherein the PDE is PDE4D3.
27 . The method of claim 23 , wherein the receptor is a RyR1 receptor.
28 . The method of claim 23 , wherein the receptor is a RyR2 receptor.
29 . The method of claim 23 , wherein the receptor is a RyR2 receptor.
30 . A method for decreasing PKA phosphorylation of a ryanodine receptor comprising contacting the ryanodine receptor complex with an agent that increases the level of PDE in the ryanodine receptor complex.
31 . The method of claim 30 , wherein the receptor is hyperphosphorylated prior to contacting the ryanodine receptor complex with the agent.
32 . The method of claim 30 , wherein the agent is selected from the group consisting of a PDE protein, a nucleic acid encoding a PDE, a member of a PDE signal-transduction pathway, and a modulator of a member of a PDE signal transduction pathway.
33 . The method of claim 30 , wherein the PDE is PDE4D.
34 . The method of claim 30 , wherein the PDE is PDE4D3.
35 . The method of claim 30 , wherein the receptor is a RyR1 receptor.
36 . The method of claim 30 , wherein the receptor is a RyR2 receptor.
37 . The method of claim 30 , wherein the receptor is a RyR3 receptor
38 . A method for regulating Ca 2+ release and reuptake in the sarcoplasmic reticulum of a cell comprising contacting a ryanodine receptor complex of the cell with an agent that modulates the level of PDE, wherein contacting the ryanodine receptor complex with an agent that increases the level of PDE results in a reduction of Ca 2+ release from and reuptake into the sarcoplasmic reticulum and contacting the ryanodine receptor complex with an agent that decreases the level of PDE in the complex results in an increase of Ca 2+ release from and reuptake into the sarcoplasmic reticulum.
39 . The method of claim 38 , wherein the agent is selected from the group consisting of a PDE protein, a nucleic acid encoding a PDE, a member of a PDE signal-transduction pathway, and a modulator of a member of a PDE signal transduction pathway.
40 . The method of claim 38 , wherein the PDE is PDE4D.
41 . The method of claim 38 , wherein the PDE is PDE4D3.
42 . The method of claim 38 , wherein the receptor is a RyR1 receptor.
43 . The method of claim 38 , wherein the receptor is a RyR2 receptor.
44 . The method of claim 38 , wherein the receptor is a RyR3 receptor.
45 . A method for decreasing Ca 2+ release and reuptake in the sarcoplasmic reticulum of a cell comprising contacting a ryanodine receptor complex of the cell with an agent that increases the level of PDE.
46 . The method of claim 45 , wherein the receptor is hyperphosphorylated prior to contacting the ryanodine receptor complex with the agent.
47 . The method of claim 45 , wherein the agent is selected from the group consisting of a PDE protein, a nucleic acid encoding a PDE, a member of a PDE signal-transduction pathway, and a modulator of a member of a PDE signal transduction pathway.
48 . The method of claim 45 , wherein the PDE is PDE4D.
49 . The method of claim 45 , wherein the PDE is PDE4D3.
50 . The method of claim 45 , wherein the receptor is a RyR2 receptor.
51 . The method of claim 45 , wherein the receptor is a RyR1 receptor.